Deskripsi produk
Indikasi
Indicated as maintenance treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to platinum-based chemotherapy, particularly in patients with HRD-positive disease or a germline BRCA mutation.
Mekanisme Kerja
PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,
Farmakologi
12.1 Mekanisme Kerja PARP , PARP-1 PARP-2, DNA , PARP PARP-DNA , DNA BRCA1/2 BRCA1/2 HRD BRCA1/2 ,
Dosis dan Penggunaan
2.1 BRCA2 AKEEGA mCSPC [ (14.1)] BRCA AKEEGA mCRPC [ (14.2)] FDA , BRCA2 (BRCA2m) (mCSPC) AKEEGA 200 mg /1000 mg , 5 mg , BRCA BRCAm mCRPC AKEEGA 200 /1,
Peringatan
5.1 / AKEEGA / (MDS/AML) AMPLITUDE MAGNITUDE , AKEEGA ,MDS AML 0.6% (2/347) 0.5% (1/212), AKEEGA MDS/ AML , / DNA MDS/AML , MDS/AML, AKEEGA
Interaksi Obat
7.1 AKEEGA CYP3A4 CYP3A4 [ (12.3)] CYP3A4 CYP3A4 [ (12.3)], 7.2 AKEEGA CYP2D6 , CYP2D6 ,
Efek Samping
/ [ Peringatan(5.1)] [ Peringatan(5.2)] [ Peringatan(5.3)] [ Peringatan(5.4)] [ Peringatan(5.5)] [ Peringatan(5.6)] 223 [ Peringatan(5.7)] [ Peringatan(5.8)] 6.1
Penyimpanan
AKEEGA® AKEEGA 50 /500 , , , “N 50 A”, 60 NDC 57894-050-60 AKEEGA 100 /500 , , , “N 50 A”,
